{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:30:49Z","timestamp":1761647449345},"reference-count":94,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T00:00:00Z","timestamp":1162252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>After decades of stagnation, the prognosis of patients with follicular lymphomas (FL) has changed substantially within the last few years due to new and effective therapeutic modalities. These include myeloablative therapy followed by autologous stem cell transplantation (ASCT) in younger patients in first remission, which showed a significant prolongation of remission duration in three prospective randomised trials while the impact on overall survival still needs to be determined. Adding the anti\u2010CD 20 antibody Rituximab to conventional chemotherapy resulted in a significant increase in remission rate, remission duration and, in two of four currently available prospective randomised studies, even in a longer overall survival. A prolongation of remission duration was also seen when Rituximab was given as maintenance after cytoreductive therapy including Rituximab. Radio\u2010immunotherapy (RIT) with radioisotopes coupled to monoclonal antibodies produced encouraging data in several phase II studies. New therapeutic perspectives have also emerged from increasing insights into the biology of the disease that unravel molecular targets for novel agents, some of which have entered clinical evaluation already.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2006.06378.x","type":"journal-article","created":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T09:18:57Z","timestamp":1162286337000},"page":"191-202","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Current management of follicular lymphomas"],"prefix":"10.1111","volume":"136","author":[{"given":"Wolfgang","family":"Hiddemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,31]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00120-5"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0447"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.527"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/13928"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1205"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21913"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.025"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-008755"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3920"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000163"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703573"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"e_1_2_5_24_1","doi-asserted-by":"crossref","first-page":"684a","DOI":"10.1182\/blood.V106.11.2434.2434","article-title":"CpG Oligonucleotide (1018 ISS) may overcome Rituximab (R) resistance in follicular lymphoma (FL) through enhanced ADCC, T cell expansion, and alteration of tumor microenvironment","volume":"106","author":"Friedberg J.W.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.3173"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0622"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/00313020500370192"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.08.010"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_5_36_1","doi-asserted-by":"crossref","first-page":"584a","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Results of a prospective randomised open label phase III study comparing Rituximab plus Mitoxantrone, Chlorambucil, Prednisolone chemotherapy (R\u2010MCP) versus MCP alone in untreated advanced indolent non\u2010Hodgkin's lymphoma (NHL) and mantle\u2010cell\u2010lymphoma (MCL)","volume":"104","author":"Herold M.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_5_38_1","first-page":"566","article-title":"Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Hiddemann W.","year":"2005","journal-title":"Proceedings of the American Social and Clinical Oncology"},{"key":"e_1_2_5_39_1","first-page":"556","article-title":"Results of E 1496: a phase III trial of CVP with or without maintenance Rituximab in advanced indolent lymphoma (NHL)","volume":"23","author":"Hochster H.S.","year":"2004","journal-title":"Proceedings of the American Social and Clinical Oncology"},{"key":"e_1_2_5_40_1","doi-asserted-by":"crossref","first-page":"106a","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B","volume":"106","author":"Hochster H.S.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1259"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3595"},{"issue":"2","key":"e_1_2_5_46_1","first-page":"29","article-title":"Cytological and functional criteria for the classification of malignant lymphomata","volume":"31","author":"Lennert K.","year":"1975","journal-title":"British Journal of Cancer"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0982"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.016"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.803"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_5_55_1","doi-asserted-by":"crossref","first-page":"683a","DOI":"10.1182\/blood.V106.11.2428.2428","article-title":"Initial safety and efficacy results of a second\u2010generation humanized anti\u2010CD20 antibody, IMMU\u2010106 (hA20), in non\u2010Hodgkin's lymphoma","volume":"106","author":"Morschhauser F.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0693"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00780-X"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1310"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0658"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2911"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3806"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-003-1062-8"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(95)01600-L"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703891"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0287"},{"key":"e_1_2_5_69_1","doi-asserted-by":"crossref","first-page":"392a","DOI":"10.1182\/blood.V104.11.1398.1398","article-title":"In vivo downregulation of Bcl\u20102 by G3139 (G) enhances rituximab (R) anti\u2010tumor activity: effect of sequential versus concurrent G3139 Administration on survival in a lymphoma\u2010bearing SCID Mouse Model","volume":"104","author":"Ramanarayanan J.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"e_1_2_5_72_1","doi-asserted-by":"crossref","first-page":"160a","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab added to aIFN\u2003+\u2003CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA\u2010GOELAMS FL\u20102000 randomized trial in 359 patients","volume":"104","author":"Salles G.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj187"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_5_75_1","first-page":"354a","article-title":"Comparison of CHVP\u2003+\u2003Interferon with followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial (G.E.L.A. Study Group)","volume":"102","author":"Sebban C.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050016"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.6577"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2273::AID-CNCR9>3.0.CO;2-V"},{"key":"e_1_2_5_80_1","doi-asserted-by":"crossref","first-page":"720a","DOI":"10.1182\/blood.V104.11.2633.2633","article-title":"Efficacy and safety of Yttrium\u201090 (90Y) Ibritumomab Tiuxetan (Zevalin) Therapy with Rituximab maintenance in patients with untreated low\u2010grade follicular lymphoma","volume":"104","author":"Sweetenham J.W.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704118"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05194.x"},{"key":"e_1_2_5_85_1","first-page":"169a","article-title":"Chimeric anti\u2010CD 20 monoclonal antibody (Rituximab, Mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non\u2010Hodgkin's lymphoma: a phase III randomized intergroup clinical trial","volume":"104","author":"Van Oers M.H.J.","year":"2005","journal-title":"Proceedings of the American Society of Hematology"},{"key":"e_1_2_5_86_1","doi-asserted-by":"crossref","first-page":"107a","DOI":"10.1182\/blood.V106.11.17.17","article-title":"Bortezomib plus rituximab in patients with indolent non\u2010Hodgkin's lymphoma (NHL): a phase 2 study","volume":"106","author":"De Vos S.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1316"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1812"},{"key":"e_1_2_5_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_2_5_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.003"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01747-3"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_5_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_5_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2006.06378.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2006.06378.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:55:59Z","timestamp":1697403359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2006.06378.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,31]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1365-2141.2006.06378.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06378.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,31]]},"assertion":[{"value":"2006-10-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}